ECSP055748A - Composiciones de liberacion controlada - Google Patents
Composiciones de liberacion controladaInfo
- Publication number
- ECSP055748A ECSP055748A EC2005005748A ECSP055748A ECSP055748A EC SP055748 A ECSP055748 A EC SP055748A EC 2005005748 A EC2005005748 A EC 2005005748A EC SP055748 A ECSP055748 A EC SP055748A EC SP055748 A ECSP055748 A EC SP055748A
- Authority
- EC
- Ecuador
- Prior art keywords
- matrix
- release
- agent
- controlled release
- release compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Una formulación de dosis sólida que tiene un núcleo con un agente farmacológico disperso en un primer aglomerante de liberación controlada del cual la liberación del agente es relativamente lenta; y una cubierta formada sobre el núcleo y que tiene un agente disperso en un segundo aglomerante de liberación controlada del cual la liberación del agente es relativamente rápida. El primer aglomerante puede ser un almidón elevado en amilosa degradada y el segundo aglomerante puede ser una mezcla de acetato de polivinilo y polivinilpirrolidona.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50906202P | 2002-10-25 | 2002-10-25 | |
US28102602A | 2002-10-25 | 2002-10-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP055748A true ECSP055748A (es) | 2005-08-11 |
Family
ID=34976756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2005005748A ECSP055748A (es) | 2002-10-25 | 2005-04-25 | Composiciones de liberacion controlada |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1558935B1 (es) |
JP (1) | JP2006507276A (es) |
KR (1) | KR101120729B1 (es) |
AT (1) | ATE400819T1 (es) |
AU (1) | AU2003275854B9 (es) |
BR (1) | BR0315657A (es) |
CA (1) | CA2503361C (es) |
DE (1) | DE60322091D1 (es) |
DK (1) | DK1558935T3 (es) |
EC (1) | ECSP055748A (es) |
ES (1) | ES2310686T3 (es) |
HK (1) | HK1086475A1 (es) |
MX (1) | MXPA05004410A (es) |
NO (1) | NO20052515L (es) |
NZ (1) | NZ539869A (es) |
PT (1) | PT1558935E (es) |
RU (1) | RU2333745C2 (es) |
SI (1) | SI1558935T1 (es) |
WO (1) | WO2004038428A2 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI319713B (en) | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
JP2005306778A (ja) * | 2004-04-21 | 2005-11-04 | Basf Ag | 徐放性製剤及びその製造方法 |
JP5563735B2 (ja) | 2004-06-16 | 2014-07-30 | タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド | Ppi多回剤形 |
CA2491665A1 (fr) * | 2004-12-24 | 2006-06-24 | Louis Cartilier | Formulation de comprime pour liberation soutenue de principe actif |
EP1917000A2 (en) | 2005-07-07 | 2008-05-07 | Farnam Companies, Inc. | Sustained release pharmaceutical compositions for highly water soluble drugs |
ES2389666T3 (es) * | 2005-09-09 | 2012-10-30 | Angelini Labopharm, Llc | Composición de trazodona para una administración de una vez al día |
CN100437113C (zh) * | 2006-04-11 | 2008-11-26 | 汪运山 | 一种检测血液中非那西丁与醋氨酚浓度比值的试剂盒 |
AU2013202441B2 (en) * | 2006-04-26 | 2016-02-25 | Alphapharm Pty Ltd | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix |
HUE029173T2 (hu) | 2006-04-26 | 2017-02-28 | Alphapharm Pty Ltd | Szabályozott hatóanyag-leadású készítmények, amelyek tartalmaznak nem bevont diszkrét egység(ek)et és egy késleltetett hatóanyag-leadású mátrixot |
CN100387988C (zh) * | 2006-07-25 | 2008-05-14 | 山东省医药工业研究所 | 一种布洛伪麻那敏复方制剂的含量检测方法 |
AU2008213744B2 (en) | 2007-02-09 | 2013-12-05 | Alphapharm Pty Ltd | A dosage form containing two or more active pharmaceutical ingredients in different physical forms |
MX336494B (es) | 2007-10-16 | 2016-01-21 | Paladin Labs Inc | Composicion de bicapas para la liberacion controlada de acetaminofeno y tramadol. |
PT2293794E (pt) | 2008-05-27 | 2013-07-10 | Univ Melbourne | Métodos de tratamento de mamíferos com disfunções da trompa de eustáquio |
EP2448406B1 (en) | 2009-02-26 | 2016-04-20 | Relmada Therapeutics, Inc. | Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use |
EP2488029B1 (en) | 2009-09-30 | 2016-03-23 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
EP2563349A4 (en) * | 2010-04-23 | 2014-03-19 | Paladin Labs Inc | NON-INTRAVENOUS-MODIFIED FORM COMPRISING A SOLID FORMULATION OF A BIOLOGICALLY ACTIVE LIQUID AGENT AND USES THEREOF |
RU2451680C1 (ru) | 2011-02-21 | 2012-05-27 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство |
CN104968333B (zh) | 2012-11-30 | 2018-07-10 | 阿库拉制药公司 | 活性药物成分的自调节释放 |
WO2017040607A1 (en) | 2015-08-31 | 2017-03-09 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
CN114177155B (zh) * | 2020-09-08 | 2023-10-03 | 越洋医药开发(广州)有限公司 | 一种布洛芬控释片及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL109460A (en) * | 1993-05-10 | 1998-03-10 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
DE19530575A1 (de) * | 1995-08-19 | 1997-02-20 | Gruenenthal Gmbh | Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz |
CA2173818A1 (fr) * | 1996-04-10 | 1997-10-11 | Francois Chouinard | Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose |
CA2270975C (en) * | 1997-07-02 | 2003-04-01 | Euro-Celtique, S.A. | Stabilized sustained release tramadol formulations |
US6284273B1 (en) * | 1998-02-24 | 2001-09-04 | Vincent Lenaerts | Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds |
DE10014588A1 (de) * | 2000-03-27 | 2001-10-04 | Basf Ag | Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung |
DE10015479A1 (de) * | 2000-03-29 | 2001-10-11 | Basf Ag | Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität |
US6607748B1 (en) * | 2000-06-29 | 2003-08-19 | Vincent Lenaerts | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
EP1248599B1 (de) * | 2001-01-31 | 2007-12-05 | Evonik Röhm GmbH | Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen |
-
2003
- 2003-10-27 RU RU2005115883/15A patent/RU2333745C2/ru not_active IP Right Cessation
- 2003-10-27 DE DE60322091T patent/DE60322091D1/de not_active Expired - Lifetime
- 2003-10-27 EP EP03809236A patent/EP1558935B1/en not_active Expired - Lifetime
- 2003-10-27 NZ NZ539869A patent/NZ539869A/en not_active IP Right Cessation
- 2003-10-27 KR KR1020057007088A patent/KR101120729B1/ko active IP Right Grant
- 2003-10-27 WO PCT/CA2003/001637 patent/WO2004038428A2/en active IP Right Grant
- 2003-10-27 JP JP2004545654A patent/JP2006507276A/ja not_active Withdrawn
- 2003-10-27 AT AT03809236T patent/ATE400819T1/de active
- 2003-10-27 SI SI200331377T patent/SI1558935T1/sl unknown
- 2003-10-27 CA CA2503361A patent/CA2503361C/en not_active Expired - Fee Related
- 2003-10-27 DK DK03809236T patent/DK1558935T3/da active
- 2003-10-27 AU AU2003275854A patent/AU2003275854B9/en not_active Expired
- 2003-10-27 BR BR0315657-5A patent/BR0315657A/pt active IP Right Grant
- 2003-10-27 PT PT03809236T patent/PT1558935E/pt unknown
- 2003-10-27 ES ES03809236T patent/ES2310686T3/es not_active Expired - Lifetime
- 2003-10-27 MX MXPA05004410A patent/MXPA05004410A/es active IP Right Grant
-
2005
- 2005-04-25 EC EC2005005748A patent/ECSP055748A/es unknown
- 2005-05-25 NO NO20052515A patent/NO20052515L/no not_active Application Discontinuation
-
2006
- 2006-06-02 HK HK06106374A patent/HK1086475A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR101120729B1 (ko) | 2012-04-23 |
PT1558935E (pt) | 2008-10-16 |
EP1558935A2 (en) | 2005-08-03 |
RU2333745C2 (ru) | 2008-09-20 |
DK1558935T3 (da) | 2008-11-17 |
CA2503361A1 (en) | 2004-05-06 |
WO2004038428A3 (en) | 2005-06-09 |
NZ539869A (en) | 2007-09-28 |
EP1558935B1 (en) | 2008-07-09 |
NO20052515D0 (no) | 2005-05-25 |
CA2503361C (en) | 2012-02-28 |
KR20050088281A (ko) | 2005-09-05 |
RU2005115883A (ru) | 2006-01-27 |
HK1086475A1 (en) | 2006-09-22 |
WO2004038428A2 (en) | 2004-05-06 |
BR0315657A (pt) | 2005-09-13 |
SI1558935T1 (sl) | 2008-12-31 |
DE60322091D1 (de) | 2008-08-21 |
AU2003275854B2 (en) | 2008-09-11 |
ATE400819T1 (de) | 2008-07-15 |
MXPA05004410A (es) | 2005-11-23 |
JP2006507276A (ja) | 2006-03-02 |
AU2003275854A1 (en) | 2004-05-13 |
ES2310686T3 (es) | 2009-01-16 |
AU2003275854B9 (en) | 2009-08-27 |
NO20052515L (no) | 2005-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055748A (es) | Composiciones de liberacion controlada | |
ME00482B (me) | Čvrste farmaceutske kompozicije koje sadrže pregabalin sredstvo za formiranje matriksa i sredstvo za bubrenje | |
AR001405A1 (es) | Formulación oral de 2-metil-tieno-beno-diacepina. | |
ME00391B (me) | Tableta bupropion hidrohlorida sa modifikovanim otpuštanjem | |
NZ515359A (en) | Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol | |
TWI235068B (en) | Sustained-release pharmaceutical composition | |
MX9707585A (es) | Mezclas homogeneas de farmacos y aditivos de fusion a baja temperatura para liberacion controlada. | |
RS54929B1 (sr) | Formulacija i metod obložene tablete | |
AR024492A1 (es) | Formas de dosificacion farmaceutica para liberacion controlada que comprenden al menos un impulso ciclico | |
JO2555B1 (en) | Forms of oral doses of propiferine or pharmaceutically acceptable salts thereof with an extended release of active agent | |
PL1631251T3 (pl) | Tabletka o opóźnionym uwalnianiu i o określonej geometrii | |
NO20033653L (no) | Ny filmcoating | |
ATE536862T1 (de) | Retardtabletten mit hydromorphon | |
WO2007025182A3 (en) | Drug compositions containing controlled release hypromellose matrices | |
AR099437A2 (es) | Matriz para la liberación sostenida, invariable e independiente de compuestos activos | |
ATE185266T1 (de) | Schnell auflösende orale darreichungsform | |
MY142195A (en) | Controlled-release compositions | |
UA86929C2 (ru) | Композиция с контролируемым высвобождением | |
ATE479428T1 (de) | Olanzapin enthaltende pharmazeutische zusammensetzung | |
BRPI0315657B8 (pt) | formulação de dosagem sólida, comprimido para liberação controlada, método de fabricar uma medicação de liberação controlada, composição farmacêutica e uso de uma composição | |
ECSP961693A (es) | Formulacion oral de 2- metil-tieno-benzodiaceptina |